HEADLINES
More than a third of patients on Wegovy pill are new to GLP-1 drugs - report
Early data shows that 36% of patients using Novo Nordisk’s new Wegovy weight-loss pill had never taken a GLP-1 medication before, while others switched from injectable versions like Wegovy or Eli Lilly’s Zepbound. The findings come from a Truveta study of 8,762 U.S. patients following FDA approval in December 2025.
Robin Respaut/Reuters
February 12, 2026
FILE PHOTO: Wegovy pens are sorted at a packaging line at Novo Nordisk's facility in Hillerod, Denmark, March 8, 2024.
Tom Little/Reuters
Among early users of Novo Nordisk's NOVOb.COnew Wegovy weight-loss pill, 36% had no prior experience taking a GLP-1 medication, a new study from the health data firm Truveta found.
Of patients who started a new pill prescription, 21.1% had previously taken the injectable version of Wegovy and 15.8% switched from Eli Lilly's LLY.N Zepbound, another injectable GLP-1 medicine, according to Truveta data.
Truveta reviewed health records from 8,762 patients with evidence of a prescription for the new Wegovy pill, which was approved by the U.S. Food and Drug Administration on December 22.
-Robin Respaut/Reuters
TOP HEALTH STORIES
Add a Title
Kennedy to tout new food policies but skip vaccines in remarks to US Congress
Prince Harry talks mental health with charity workers at Melbourne football club
Tylenol in pregnancy not linked with autism, Danish study finds
LATEST NEWS
Add a Title
Pope Leo, in Cameroon, decries world 'ravaged by tyrants'
Archbishop of Canterbury backs Pope Leo's call for peace
EXPLAINER: How El Nino-driven weaker monsoon rains could impact India
PARALUMAN NEWS
GET IN TOUCH
desk@myparaluman.ph
Tektite Towers (East), Exchange Road
Ortigas Center. San Antonio 1600
City of Pasig, NCR, Philippines
MENU
EDITORIAL STANDARDS
© 2025 Paraluman News Publication